Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss
March 28, 2019 4:14 PM EDTBiocept (NASDAQ: BIOC) reported Q4 EPS of ($1.43), $0.15 better than the analyst estimate of ($1.58). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $930 thousand.
"Revenues and billable samples for the fourth quarter reached their highest levels in 2018, as we benefited from our refocused commercial strategy," said Michael Nall, President and CEO of Biocept. "Our efforts to enhance our growth in test volumes has continued into 2019.
"A key driver of growth is the relaunch of our... More
